Tempest Therapeutics Signs Strategic Partnership With Senlang to Advance TPST‑4003 In Vivo CAR‑T Candidate in China
Tempest Therapeutics, Inc. (NASDAQ: TPST) announced a strategic partnership with Hebei Senlang Biotechnology Co., Ltd....
Zhaoke Ophthalmology Signs Strategic MOU With Brazil’s Teuto at BIO 2026 – First Latin America Eye‑Care Market Entry
Zhaoke Ophthalmology Limited (HKG: 6622) announced that it signed a strategic cooperation memorandum with Brazilian...
GRIT Biotechnology and Drug Farm Sign Deep Collaboration Agreement to Co‑Create KunEvo, an AI‑Native Biotech R&D Platform for First‑in‑Class Drug Discovery
GRIT Biotechnology and Sino-US biotech company Drug Farm jointly announced a deep agreement to collaborate...
Hangzhou Eli Radiopharma and Shanghai Smartlogic Sign Strategic Cooperation Agreement to Advance Computation‑Driven Radiopharmaceutical Discovery and Co‑Build Cyclic Peptide Platform
Hangzhou Eli Radiopharma Co., Ltd. and Shanghai Smartlogic Technology Ltd. officially signed a strategic cooperation...
Sun-Novo and GemPharmatech Sign Long‑Term Strategic Cooperation Agreement to Deepen Preclinical Collaboration on Small Nucleic Acid Therapeutics and Build Closed‑Loop AOC R&D System
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) and GemPharmatech Inc. (SHA: 688046) officially signed...
Gan & Lee Pharmaceuticals Signs Out‑Licensing Deal With Menarini on Bonfaglutide, a Twice‑Monthly GLP‑1 RA, Worth Up to EUR 726 Million Across 39 European Markets
Gan & Lee Pharmaceuticals (SHA: 603087) announced an out‑licensing agreement with Menarini for Bonfaglutide Injection...
Zhifei Biological Submits Clinical Trial Application in China for Nasal Spray Recombinant RSV Vaccine Based on Chimpanzee Adenovirus Vector
Zhifei Biological (SHE: 300122) announced that it has submitted a clinical trial application in China...
Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps
Keymed Biosciences Inc. (HKG: 2162) announced that the Phase 2 trial of CM512 injection, a...
Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First‑in‑Class KCNT1 Ion Channel Inhibitor ABS‑1230 for Ultra‑Rare Epilepsy
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced that it will acquire Actio Biosciences, a privately held biopharmaceutical...
CSPC Pharmaceutical Group’s Monkeypox mRNA Vaccine SYS6037 Receives FDA Approval to Conduct Clinical Trials in the US
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Category 1 preventive biologic product SYS6037...
Novo Nordisk Names AWS Preferred Cloud Provider and Strategic AI Partner to Accelerate Drug Discovery With Agentic AI
Novo Nordisk (NYSE: NVO) and Amazon Web Services (AWS) announced a strategic partnership to accelerate...
Xbiome and BioMap Sign Strategic Cooperation Agreement to Advance AI‑Powered Microbiome Drug and Probiotic Product R&D
Xbiome, a China‑based AI‑driven microbiome drug development company, and BioMap officially signed a strategic cooperation...
BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced a multifaceted collaboration agreement with...
BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection)...
Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting‑edge...
Astellas Submits NDA in Japan for Fezolinetant, a First-in-Class Nonhormonal NK3 Receptor Antagonist for Menopausal Vasomotor Symptoms
Astellas Pharma Inc. (TYO: 4503) announced that it has submitted a New Drug Application (NDA)...
Xtalpi and Gan & Lee Pharmaceuticals’ AI Peptide Delivery Lab Recognized as Beijing Key Laboratory, Deepening AI‑Powered Peptide Drug R&D Collaboration
XtalPi Inc. (HKG: 2228) and Gan & Lee Pharmaceuticals (SHA: 603087) announced that their jointly...
CrystalO Biopharma Signs Collaboration and Licensing Deal With Almirall for AI‑Driven Skin Disease Drug Discovery, Worth Up to €254.5 Million
CrystalO Biopharma Co., Ltd. announced that it has entered into a collaboration and licensing agreement...
Tonghua Golden‑Horse Unit Signs M&A Intent Agreement to Acquire Controlling Stake in 8PLUS1 Pharma
Guilin Golden-Horse Innovation Investment Co., Ltd., a wholly owned subsidiary of Tonghua Golden-Horse Pharmaceutical Industry...
Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases
Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US‑based Statia Biopharma,...